SuperAPI AI Directory
Partner with us中文AI newsFavorites
Skillsip-strategy

ip-strategy

General & other

View repository

Updated 10-15 23:43

About this skill

IP Strategy

Required Inputs

  • IP Portfolio Inventory: List of IP assets (patents, trademarks, trade secrets, copyrights, know-how, software, data assets) with registration details and current ownership.
  • Group Structure: Entities, jurisdictions, and ownership chain.
  • DEMPE Functions: Where IP Development, Enhancement, Maintenance, Protection, and Exploitation activities are currently performed.
  • IP-Related Financial Data: Revenue attributable to IP, current royalty flows, R&D expenditure, IP-related costs by entity.
  • Strategic Objectives: Tax optimization, IP centralization, M&A preparation, risk mitigation, or licensing monetization.
  • Jurisdictions of Interest: Current and planned IP holding locations.
  • Existing Agreements: Current license agreements, cost sharing arrangements, and R&D service agreements.
  • Regulatory Context: Industry-specific IP regulations, data localization requirements, and export control considerations.

Execution Steps

1. IP Asset Identification and Classification

Conduct a comprehensive IP inventory:

IP Asset Type Description Owner (Legal) Owner (Economic) Registration / Status Jurisdiction Revenue Attributable ($M) Remaining Useful Life
[Asset 1] Patent [Description] [Entity] [Entity] [Granted / Pending / Trade secret] [Country] $___M ___ years
[Asset 2] Trademark [Description] [Entity] [Entity] [Registered / Common law] [Country] $___M Indefinite
[Asset 3] Trade secret [Description] [Entity] [Entity] [Internal classification] [Country] $___M N/A
[Asset 4] Copyright [Description] [Entity] [Entity] [Auto / Registered] [Country] $___M ___ years
[Asset 5] Know-how [Description] [Entity] [Entity] [Documented / Undocumented] [Country] $___M ___ years
[Asset 6] Data asset [Description] [Entity] [Entity] [Proprietary / Licensed] [Country] $___M ___ years

IP classification matrix:

Classification Tax Relevance Valuation Approach Licensing Model
Patents Qualify for IP box in most regimes; amortizable; can be contributed tax-free under certain conditions Relief from royalty, excess earnings Royalty as % of net sales (typical: 2-8%)
Trademarks IP box eligibility varies (excluded in many post-BEPS regimes); indefinite life Relief from royalty, market approach Royalty as % of net sales (typical: 1-5%)
Trade secrets May qualify as know-how for IP box; no registration = harder to transfer cleanly Cost approach, excess earnings Lump-sum or running royalty
Copyrights / software Software copyrights qualify for IP box in many jurisdictions; finite life Relief from royalty, cost approach Per-unit, per-user, or % of revenue
Know-how Qualifies if documented and transferable; DEMPE analysis critical Cost approach, comparable transactions Technical assistance fee or bundled royalty
Data assets Emerging area; limited IP box coverage; privacy regulations create complexity Cost approach, income approach License fee, data-as-a-service pricing

2. IP Ownership Structure Design

Evaluate alternative ownership structures:

Structure Description Tax Advantages Tax Risks Best Suited For
Centralized IP HoldCo Single entity owns all material IP; licenses to operating entities worldwide IP box eligibility; consolidated royalty income; single licensing point Substance challenge (DEMPE must be performed); withholding on royalties; CFC risk at parent level Groups with globally exploited IP; post-M&A IP consolidation
Regional IP HoldCos IP ownership split by region (e.g., EMEA, APAC, Americas) Regional treaty access; reduced withholding; distributed risk Complexity; fragmented ownership; potential for inconsistent policies Large multinationals with distinct regional markets
Distributed / local ownership Each operating entity owns IP it develops and uses locally Simplest; no intercompany royalties; substance automatic No centralized IP box benefit; no royalty deductions in high-tax jurisdictions Early-stage companies; single-jurisdiction businesses
Principal company model One entity is the entrepreneur/principal; owns IP and bears risk; other entities are limited-risk Aligns with FAR analysis; residual profit in IP owner; routine returns to others Principal must have genuine substance and decision-making authority Groups with clear entrepreneurial entity
Cost sharing arrangement Multiple participants jointly fund IP development and share ownership proportional to anticipated benefit Each participant owns right to exploit in its territory; no ongoing royalty Buy-in payment on existing IP; complex to maintain; IRS scrutiny (Section 482) Joint development between US parent and foreign subsidiary

Recommended structure evaluation:

Factor Option A: Centralized HoldCo in [Country] Option B: Principal Model in [Country] Option C: Cost Sharing
IP box rate available ___% ___% N/A
Withholding on royalties (weighted avg) ___% ___% N/A (no royalties)
DEMPE substance achievable? [Assessment] [Assessment] Automatic (development = ownership)
CFC inclusion risk [Assessment] [Assessment] [Assessment]
Implementation complexity [Low/Med/High] [Low/Med/High] [Low/Med/High]
Ongoing compliance cost $___K/year $___K/year $___K/year
Estimated annual tax savings $___M $___M $___M

3. IP Valuation Methodologies

Cross-reference to the valuation skill for full methodology. Key approaches for IP:

3a. Relief from Royalty Method

IP Value = Sum of [Projected Revenue_t x Royalty Rate x (1 - Tax Rate) / (1 + r)^t] for t = 1 to N
         + Terminal Value

Where:
  Royalty Rate = arm's length royalty rate from comparable license agreements
  Tax Rate = tax rate of the hypothetical licensee
  r = discount rate (risk-adjusted; typically WACC + IP-specific premium)
  N = remaining useful life of the IP
Parameter Value Basis
Projected revenue (Year 1) $___M Management forecast
Revenue growth rate ___% Historical + market analysis
Arm's length royalty rate ___% Comparable license analysis
Tax rate ___% Licensee jurisdiction
Discount rate ___% WACC + ___ bps IP premium
Remaining useful life ___ years Patent term / economic life
IP Value (Relief from Royalty) $___M

3b. Multi-Period Excess Earnings Method (MPEEM)

Used for primary intangible assets — isolates earnings attributable to the IP after deducting returns on all other assets:

Excess Earnings_t = Total Earnings_t
  - Contributory Asset Charge (working capital x required return)
  - Contributory Asset Charge (fixed assets x required return)
  - Contributory Asset Charge (workforce x required return)
  - Contributory Asset Charge (other intangibles x required return)

IP Value = Sum of [Excess Earnings_t / (1 + r)^t] for t = 1 to N + Terminal Value

3c. Cost Approach

Used as a floor value or for early-stage IP where income data is limited:

IP Value = Sum of historical R&D costs to develop the IP
         x (1 + Entrepreneurial profit margin)
         x Obsolescence adjustment (functional, economic, technological)
Cost Element Amount ($M) Period
Internal R&D labor $___M [Years]
External R&D (contractors) $___M [Years]
Materials and supplies $___M [Years]
Allocated overhead $___M [Years]
Opportunity cost / developer's profit $___M ___% markup
Less: Obsolescence adjustment ($___M) ___% reduction
IP Value (Cost Approach) $___M

Valuation reconciliation:

Method IP Value ($M) Weight Weighted Value ($M)
Relief from royalty $___M ___% $___M
Excess earnings (MPEEM) $___M ___% $___M
Cost approach $___M ___% $___M
Concluded IP Value $___M

4. Licensing Structure Design

4a. License Framework

Element Inbound License (to IP HoldCo from developer) Outbound License (from IP HoldCo to OpCo)
License type Exclusive, worldwide, all fields of use Non-exclusive, territory-specific, field-specific
Royalty basis Lump-sum buy-in + ongoing royalty Running royalty (% of net sales)
Royalty rate Market rate benchmarked to comparable transactions Market rate benchmarked to comparable transactions
Sub-licensing rights Yes — enables outbound licensing Limited — only within operating territory
Term Perpetual or IP lifetime 5-10 years, auto-renewing
Minimum royalty [If applicable] [If applicable to ensure substance of arrangement]
Payment timing Quarterly in arrears Quarterly in arrears

4b. Royalty Rate Benchmarking

Comparability Factor Comparable 1 Comparable 2 Comparable 3 Subject Transaction
Industry [Industry] [Industry]
IP type [Patent/TM/SW]
Exclusivity [Exclusive/Non-exclusive]
Territory [Scope]
Development stage [Early/Mature]
Revenue base [Net sales / Gross sales]
Royalty rate ___% ___% ___%
Arm's length range ___% - ___%
Selected rate ___%

Data sources for royalty comparables: RoyaltyStat, ktMINE, SEC filings (license agreements in 10-K/10-Q), BVR/Valuation Advisors, industry surveys.

4c. Withholding Tax on Royalties

Royalty Flow From (Licensee) To (Licensor) Domestic WHT Rate Treaty Rate Treaty Cited Beneficial Owner Test Met?
[Flow 1] [Entity/Country] [Entity/Country] ___% ___% [Treaty article] Yes/No
[Flow 2]

Net royalty income after WHT and IP box:

Net income = Gross royalty
  - Withholding tax (net of foreign tax credits)
  x IP box effective rate (if applicable)
  = After-tax royalty income

5. IP Migration Planning

5a. Migration Step Plan

Step Action Tax Implication Timeline
1 IP valuation — Determine arm's length value of IP to be transferred Valuation sets the transfer price; affects gain/loss at transferor Weeks 1-6
2 Exit tax analysis — Quantify tax on deemed disposition at transferor jurisdiction Transferor recognizes gain = FMV minus tax basis; exit tax may apply Weeks 1-4 (concurrent)
3 Transfer pricing documentation — Prepare documentation supporting arm's length consideration Required to defend transfer price; contemporaneous documentation essential Weeks 4-8
4 Intercompany agreement execution — IP assignment or license agreement at arm's length Legal transfer of rights; consideration may be lump-sum, installment, or ongoing payment Week 8
5 Regulatory filings — Patent/trademark assignment recordings; tax authority notifications Some jurisdictions require advance notification of IP transfers (e.g., Australia, India) Weeks 8-12
6 Substance establishment — Ensure receiving entity has DEMPE capability before or at transfer Substance must exist before IP income flows; retroactive substance does not cure Weeks 1-8 (must precede step 4)
7 Post-migration monitoring — Verify intercompany flows align with new structure Ensure royalties are paid on schedule; TP documentation updated annually Ongoing

5b. Exit Tax Analysis

Jurisdiction Exit Tax Rule Applies to IP Transfers? Rate Deferral / Exemption Available?
United States Section 367(d) — deemed royalty over useful life (not lump-sum) Yes — outbound IP transfers to foreign corp Ordinary income rates (up to 37% individual / 21% corporate) No deferral; 20-year deemed income inclusion
Germany Exit tax on unrealized gains when assets leave German tax jurisdiction Yes ~30% (corporate + trade tax) EU/EEA deferral (5 annual installments)
France Exit tax on unrealized gains Yes ~25% EU/EEA deferral under conditions
Australia CGT on deemed disposal; market value substitution rule Yes 30% (corporate) No general deferral
India Tax on IP transfer; requires prior AO approval for some transfers Yes As per transfer pricing + capital gains rates No
Netherlands Generally no exit tax on IP (participation exemption may apply to IP gains) Limited N/A Participation exemption may shelter gain
UK Degrouping charge if transferred within 6 years of intra-group transfer Conditional 25% (corporate) Substantial shareholding exemption may apply

Exit tax cost estimate:

IP Asset FMV ($M) Tax Basis ($M) Gain ($M) Exit Tax Rate Exit Tax ($M) Mitigation
[Asset 1] $___M $___M $___M ___% $___M [Strategy]
[Asset 2] $___M $___M $___M ___% $___M [Strategy]
Total exit tax $___M

Break-even analysis: Years to recoup exit tax through lower ongoing IP income taxation:

Break-even period = Exit tax cost / Annual tax saving from new structure

6. Cost Sharing / Cost Contribution Arrangement (CCA) Design

Element Design Decision Rationale
Participants [List entities and territories] Each must reasonably anticipate benefit from IP
Scope of IP [Specific IP being jointly developed] Clearly defined to avoid scope creep disputes
Cost pool [R&D costs, direct and indirect] All costs related to developing the covered IP
Allocation key [Reasonably anticipated benefits — typically projected revenue or operating profit by territory] Must reflect anticipated benefit, not actual results
Buy-in payment [Lump-sum or installment for pre-existing IP contributed] Arm's length value of existing IP made available to the arrangement
Buy-out provisions [Payment if participant exits arrangement] Must reflect FMV of interest relinquished
PCT payments (US) [Platform Contribution Transaction — arm's length consideration for existing IP] Required under Section 482 cost sharing regulations
Annual true-up [Mechanism to adjust if actual costs differ from projections] Ensures ongoing arm's length allocation

CCA vs. licensing comparison:

Factor Cost Sharing / CCA Licensing Model
Upfront cost High (buy-in for pre-existing IP) Low (no buy-in)
Ongoing payments Share of R&D costs (proportional to anticipated benefit) Royalty (% of revenue or profits)
IP ownership Each participant owns rights in its territory Licensor retains ownership; licensee has use rights only
DEMPE alignment Each participant must perform DEMPE for its territory Licensor performs DEMPE; licensee performs exploitation only
Flexibility to exit Buy-out payment required License termination per agreement terms
IRS/tax authority scrutiny High (Section 482 regulations; Altera case history) Moderate (standard arm's length analysis)
Best for Genuinely joint development with shared expertise IP owner controls development; licensees exploit locally

7. DEMPE Functions Substance Requirements

The OECD Guidelines (Chapter VI) require that the entity claiming IP income must perform — or control and bear the financial risk of — the DEMPE functions:

DEMPE Function Description Substance Indicators Minimum Requirements
Development Creating and improving the IP R&D personnel; lab/development facilities; decision authority over R&D direction Qualified employees directing R&D strategy; budget authority
Enhancement Upgrading and extending the IP Engineers/scientists improving existing IP; versioning; feature additions Personnel working on IP improvements; documented enhancement roadmap
Maintenance Preserving the value and utility of the IP Quality assurance; bug fixes; renewals; patent maintenance fees Staff maintaining IP; budget for maintenance activities
Protection Legal and practical protection of IP rights IP counsel; patent prosecution; litigation management; trade secret programs Legal team or supervised external counsel; IP protection policies
Exploitation Commercializing and monetizing the IP Licensing negotiations; marketing strategy; pricing decisions; distribution Commercial decision-makers; licensing/sales team

Substance assessment per entity:

Entity D E M P E Overall Substance Rating Gap
[IP HoldCo] [Strong/Adequate/Weak] [Sufficient / Insufficient] [Description]
[R&D Entity] [Strong/Adequate/Weak]
[OpCo 1] [Strong/Adequate/Weak]

Minimum substance benchmarks for IP holding entities:

Requirement Benchmark Current Status Action Needed
Qualified employees 3-5 minimum with IP management expertise [Current count] [Hire / Relocate]
Board / management Local directors with authority over IP decisions [Current composition] [Appoint / Empower]
Office and facilities Genuine office (not just registered address) [Current setup] [Lease / Expand]
Operating expenditure Proportional to IP income (no empty shell) $___M current [Increase / Justify]
Decision-making records Board minutes documenting IP strategy decisions [Available / Not available] [Implement governance protocol]
Contracts with service providers Outsourced DEMPE functions under HoldCo's control and direction [In place / Missing] [Draft service agreements]

8. IP Box Regime Eligibility and Benefit Analysis

Assess eligibility for IP box in the IP holding jurisdiction:

Requirement Threshold Entity Status Eligible?
Qualifying IP type [Per regime — patents, software, etc.] [IP types held] Yes/No
Nexus fraction Must be >0%; benefit scales with fraction ___% (see calculation below) Yes — ___% of income qualifies
Income tracking IP income must be tracked per qualifying asset [System in place / Not in place] Yes/No
Election / registration [Per regime requirements] [Filed / Not filed] Yes/No
Minimum holding period [If applicable] [Holding period met?] Yes/No

Nexus fraction calculation:

Nexus Fraction = (QE + UPE) / OE

Where:
  QE = Qualifying Expenditure (in-house R&D + outsourced R&D to unrelated parties)
  UPE = Uplift (30% of QE, capped so QE + UPE does not exceed OE)
  OE = Overall Expenditure (QE + acquisition cost of IP + outsourced R&D to related parties)
Component Amount ($M) Notes
In-house R&D expenditure $___M Employees performing qualifying R&D
Outsourced R&D (unrelated parties) $___M Third-party R&D contractors
Qualifying Expenditure (QE) $___M Sum of above
30% Uplift (UPE) $___M Min(30% x QE, OE - QE)
Numerator (QE + UPE) $___M
IP acquisition cost $___M Purchase price of acquired IP
Outsourced R&D (related parties) $___M Intercompany R&D charges
Overall Expenditure (OE) $___M QE + acquisition + related-party outsourcing
Nexus Fraction ___% (QE + UPE) / OE

Benefit calculation:

IP box benefit = Qualifying IP income x Nexus fraction x (Standard rate - IP box rate)
Annual benefit = $___M x ___% x (___% - ___%) = $___M

9. Defensive IP Strategy

Component Analysis Recommendation
Freedom to operate (FTO) [Assessment of third-party IP that could block commercial activities] [Obtain licenses / Design around / Challenge validity]
IP audit [Review of all IP assets for proper documentation, registration, and protection] [Register unregistered IP; document trade secrets; update assignments]
Employee IP agreements [Status of IP assignment clauses in employment contracts] [Standardize across jurisdictions; include post-employment restrictions]
Contractor IP agreements [Status of IP ownership clauses in contractor agreements] [Ensure work-for-hire or assignment; address pre-existing IP]
IP insurance [Coverage for infringement claims, both defensive and offensive] [Evaluate IP insurance policies; cost-benefit analysis]
Trade secret program [Status of trade secret identification, classification, and protection measures] [Implement classification system; access controls; NDA program]
Enforcement strategy [Approach to monitoring and enforcing IP rights against infringers] [Watch services; graduated enforcement (cease-and-desist, negotiation, litigation)]
Open source compliance [Review of open source software usage and license compliance] [Audit; implement approval workflow; ensure license compatibility]

10. IP in M&A Context

Scenario Tax Considerations Recommended Approach
IP acquisition (asset deal) Buyer allocates purchase price to IP (Section 1060 allocation); amortizes over 15 years (Section 197) or useful life Maximize allocation to short-lived / depreciable IP; step-up benefit calculation
IP carve-out (pre-sale) Transfer IP out of target before sale; may trigger gain at target; affects target valuation Evaluate exit tax vs. sale price impact; timing relative to deal signing
IP contribution to JV Section 351 (US) or local equivalent for tax-free contribution; must control resulting entity Verify control threshold; document FMV at contribution
IP licensing post-deal New intercompany IP license between acquirer group and target; arm's length royalty required Benchmark royalty rate; integrate into deal economics
IP in spin-off Section 355 requirements; IP must be part of active trade or business Verify IP is integral to spun-off business; avoid device
IP representations & warranties Target reps on IP ownership, freedom from encumbrance, non-infringement Tax indemnity for IP-related tax exposures (transfer pricing, IP box claims)

IP step-up benefit calculation (asset deal):

IP Asset Allocated Value ($M) Tax Basis Before ($M) Step-Up ($M) Amortization Period Annual Deduction ($M) Tax Rate Annual Tax Benefit ($M) NPV of Step-Up ($M)
[Asset 1] $___M $___M $___M ___ years $___M ___% $___M $___M
[Asset 2] $___M $___M $___M ___ years $___M ___% $___M $___M
Total $___M

11. Anti-Avoidance Considerations

Risk OECD Reference Description Mitigation
Nexus approach (BEPS Action 5) Action 5 Final Report IP box benefits limited by nexus fraction; substance required Maximize in-house R&D; minimize related-party outsourcing
DEMPE substance (BEPS Actions 8-10) Ch. VI, OECD Guidelines IP income must be commensurate with DEMPE functions performed Ensure IP HoldCo has real people, real decisions, real risk-bearing
Hard-to-value intangibles (HTVI) Ch. VI, Section D.4 Tax authorities may use ex-post outcomes to challenge ex-ante valuations Conservative valuation; price adjustment clauses; contemporaneous documentation
Recharacterization Ch. I, Section D.2 Tax authority may recharacterize a transaction if it lacks commercial rationality Ensure arrangement is commercially rational for all parties
Principal Purpose Test (PPT) MLI Article 7 Treaty benefits denied if principal purpose is to obtain treaty benefit Document non-tax commercial reasons for structure
CFC inclusion of IP income Various (Subpart F, GILTI, CFC rules per jurisdiction) Passive royalty income may be included in parent's income currently Active business exception; high-tax exclusion; check-the-box planning
Transfer pricing on IP transfers Ch. IX, OECD Guidelines IP migration must be at arm's length value; commensurate with income standard (US) Robust valuation; consider price adjustment mechanism
Economic substance legislation Cayman, BVI, Channel Islands, UAE, etc. Entities must demonstrate adequate substance for IP holding activities Meet minimum substance requirements per jurisdiction

Overall anti-avoidance risk rating:

Structure Element Risk Level Confidence in Defense Priority Mitigation
IP ownership location [Low/Med/High] [Strong/Adequate/Weak] [Action]
DEMPE substance [Low/Med/High] [Strong/Adequate/Weak] [Action]
Royalty pricing [Low/Med/High] [Strong/Adequate/Weak] [Action]
IP migration valuation [Low/Med/High] [Strong/Adequate/Weak] [Action]
Treaty access / WHT reduction [Low/Med/High] [Strong/Adequate/Weak] [Action]
CFC exposure [Low/Med/High] [Strong/Adequate/Weak] [Action]

12. Implementation Roadmap

Phase Timeline Actions Deliverables Dependencies
1. Assessment Weeks 1-4 IP inventory; DEMPE mapping; current structure analysis; identify target structure IP register; DEMPE matrix; options memo Access to IP records, R&D team interviews
2. Valuation Weeks 3-8 Value IP assets using appropriate methodology; benchmark royalty rates Valuation report; royalty benchmarking study Financial data; comparable license data
3. Structure Design Weeks 5-10 Select IP holding location; design license/CCA structure; draft intercompany agreements Structure memo; draft agreements Tax opinion on structure; legal review
4. Substance Building Weeks 6-16 Hire/transfer qualified employees to IP HoldCo; establish office; implement governance Employment contracts; office lease; board resolution Recruitment; immigration (if cross-border)
5. IP Migration Weeks 12-20 Execute IP assignments; file regulatory recordings; implement transfer pricing documentation Executed assignments; patent/TM recordings; TP local file Valuation complete; substance in place
6. Operational Launch Weeks 16-24 Activate licensing flows; implement royalty payment processes; update accounting systems First royalty invoices; updated intercompany accounts IT/finance systems; banking setup
7. Regulatory Filings Weeks 20-28 IP box election; tax return filings; CbCR updates; any advance ruling applications Filed elections; updated CbCR; ruling application Local tax advisor; filing deadlines
8. Monitoring Ongoing Annual DEMPE review; TP documentation update; nexus fraction recalculation; substance audit Annual compliance package Internal tax team; external advisors

Regulatory filing checklist:

Filing Jurisdiction Deadline Status
Patent/trademark assignment recording [IP offices per jurisdiction] [Varies — typically 3-6 months] [ ]
IP box election [IP HoldCo jurisdiction] [With tax return] [ ]
Transfer pricing documentation [Each jurisdiction] [With tax return or on request] [ ]
CbCR update [Parent jurisdiction] [12 months after fiscal year end] [ ]
Advance ruling application (if desired) [IP HoldCo jurisdiction] [Before implementation] [ ]
Foreign investment notification [If applicable] [Varies] [ ]
Export control license (if applicable) [Transferor jurisdiction] [Before IP transfer] [ ]

Output Template

## IP Strategy: [Client / Group Name]

**Date**: [Date] | **Prepared by**: Tax Advisory Practice
**Objective**: [IP structuring objective]

> This analysis provides a strategic framework for tax planning. It does not
> constitute tax advice or a legal opinion. Implementation requires review by
> qualified tax counsel in each relevant jurisdiction. Tax laws change
> frequently; all analysis is based on current rules as of the date provided.

---

### 1. IP Portfolio Summary

| IP Asset | Type | Owner | Revenue ($M) | Useful Life | Value ($M) |
|---|---|---|---|---|---|
| [Asset] | [Type] | [Entity] | $___M | ___ years | $___M |

**Total IP portfolio value**: $___M

### 2. Current DEMPE Analysis

| DEMPE Function | Currently Performed By | Substance Rating |
|---|---|---|
| Development | [Entity/Location] | [Strong/Adequate/Weak] |
| Enhancement | [Entity/Location] | [Strong/Adequate/Weak] |
| Maintenance | [Entity/Location] | [Strong/Adequate/Weak] |
| Protection | [Entity/Location] | [Strong/Adequate/Weak] |
| Exploitation | [Entity/Location] | [Strong/Adequate/Weak] |

### 3. Recommended IP Structure

[Narrative description with entity diagram]

**IP holding entity**: [Entity name, jurisdiction, role]
**Substance plan**: [Employees, office, governance]

### 4. IP Valuation

| Method | IP Value ($M) | Weight |
|---|---|---|
| Relief from royalty | $___M | ___% |
| Excess earnings | $___M | ___% |
| Cost approach | $___M | ___% |
| **Concluded value** | **$___M** | |

### 5. Licensing Design

| License | Licensor | Licensee | Royalty Rate | Annual Flow ($M) | WHT |
|---|---|---|---|---|---|
| [License] | [Entity] | [Entity] | ___% | $___M | ___% |

### 6. IP Migration Plan (if applicable)

| IP Asset | From | To | Value ($M) | Exit Tax ($M) | Break-Even (Years) |
|---|---|---|---|---|---|
| [Asset] | [Entity] | [Entity] | $___M | $___M | ___ |

### 7. IP Box Benefit

**Nexus fraction**: ___%
**Effective rate**: ___% (vs. standard ___%)
**Annual benefit**: $___M | **NPV (10-year)**: $___M

### 8. Anti-Avoidance Risk Assessment

| Risk | Level | Defense Strength | Mitigation |
|---|---|---|---|
| DEMPE substance | [Low/Med/High] | [Strong/Adequate/Weak] | [Action] |
| Nexus approach | [Low/Med/High] | [Strong/Adequate/Weak] | [Action] |
| CFC inclusion | [Low/Med/High] | [Strong/Adequate/Weak] | [Action] |
| HTVI challenge | [Low/Med/High] | [Strong/Adequate/Weak] | [Action] |
| Treaty PPT | [Low/Med/High] | [Strong/Adequate/Weak] | [Action] |

### 9. Defensive IP Strategy

[FTO assessment, IP audit findings, trade secret program recommendations]

### 10. Implementation Roadmap

| Phase | Timeline | Key Actions | Owner |
|---|---|---|---|
| Assessment | Weeks 1-4 | [Actions] | [Team] |
| Valuation | Weeks 3-8 | [Actions] | [Team] |
| Structure design | Weeks 5-10 | [Actions] | [Team] |
| Substance building | Weeks 6-16 | [Actions] | [Team] |
| Migration | Weeks 12-20 | [Actions] | [Team] |
| Operational launch | Weeks 16-24 | [Actions] | [Team] |

### Key Recommendations

1. [Priority recommendation with estimated benefit and timeline]
2. [Second priority recommendation]
3. [Third priority recommendation]

### Cross-References
- `valuation` skill for detailed IP valuation methodologies
- `tax-structure-advisory` skill for holding company jurisdiction selection
- `transfer-pricing` skill for royalty rate benchmarking and TP documentation
- `tax-incentive-analysis` skill for IP box eligibility and R&D credit interaction

Quality Checks

  • All analysis is clearly labeled as an analytical framework, not legal advice; disclaimer is included.
  • Complete IP inventory with classification, ownership, jurisdiction, and revenue attribution for every asset.
  • IP ownership structure options evaluated with at least three alternatives compared on tax savings, risk, and complexity.
  • IP valuation uses at least two methodologies with reconciliation and concluded value.
  • Royalty rate benchmarking uses comparable license agreements with documented comparability factors.
  • Withholding tax on royalties is analyzed for each flow with treaty rates and beneficial ownership assessment.
  • IP migration plan includes exit tax analysis with break-even calculation.
  • Cost sharing / CCA design (if applicable) includes buy-in calculation, allocation key, and annual true-up mechanism.
  • DEMPE substance analysis covers all five functions with specific indicators and minimum requirements per entity.
  • Substance requirements include minimum headcount, local management, office, and operating expenditure benchmarks.
  • IP box eligibility assessed with nexus fraction calculation per BEPS Action 5.
  • Anti-avoidance assessment covers nexus approach, DEMPE, HTVI, recharacterization, PPT, CFC, and economic substance.
  • Defensive IP strategy includes FTO, IP audit, employee/contractor agreements, and enforcement approach.
  • IP in M&A context (if applicable) includes step-up benefit NPV calculation.
  • Implementation roadmap includes phases, timeline, deliverables, dependencies, and regulatory filing checklist.
  • Cross-references to related skills (valuation, tax-structure-advisory, transfer-pricing, tax-incentive-analysis) are included.